Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879494 | 0.96 | KMT2A (0.72) | KMT2AGAAGFERARALDH1A1 | |
| SCHEMBL13879554 | 0.85 | TSHR (0.61) | KMT2AARALDH1A1MAPTTSHR | |
| SCHEMBL13879579 | 0.82 | AR (0.60) | KMT2AARALDH1A1MEN1TSHR | |
| SCHEMBL13879514 | 0.81 | ALDH1A1 (0.60) | KMT2AGAAARALDH1A1MAPT | |
| SCHEMBL5740339 | 0.80 | KMT2A (0.72) | KMT2AGAAGFERARALDH1A1 | |
| SCHEMBL13879404 | 0.79 | TSHR (0.78) | KMT2AGAAGFERALDH1A1USP2 | |
| SCHEMBL13879549 | 0.78 | AR (0.55) | KMT2AARALDH1A1MEN1TSHR | |
| SCHEMBL11167757 | 0.77 | ALDH1A1 (0.62) | KMT2AARALDH1A1MGLLMEN1 | |
| SCHEMBL10465001 | 0.77 | ALDH1A1 (0.55) | KMT2AGAAGFERARALDH1A1 | |
| SCHEMBL5740800 | 0.76 | KMT2A (0.66) | KMT2AGAAGFERARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | KMT2A 2463/4885GAA 463/4885GFER 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.